Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Zarnestra R&D Overseen By Ortho Oncology/HIV Group, Headed By Mattes

Executive Summary

Clinical development of Johnson & Johnson's farnesyl transferase inhibitor Zarnestra will be overseen by the company's tentatively named Ortho Oncology & Specialty Therapeutics business unit

You may also be interested in...



J&J Builds Oncology Presence: Zarnestra, Yondelis Slated For Filing In 2005

Johnson & Johnson expects to file NDAs for two oncologics - Zarnestra and Yondelis - as early as the first half of 2005, Pharmaceutical R&D President Harlan Weisman, MD, told analysts July 13

J&J Builds Oncology Presence: Zarnestra, Yondelis Slated For Filing In 2005

Johnson & Johnson expects to file NDAs for two oncologics - Zarnestra and Yondelis - as early as the first half of 2005, Pharmaceutical R&D President Harlan Weisman, MD, told analysts July 13

J&J Oncology/HIV Marketing Company Will Be Tibotec In U.S.

J&J will use the Tibotec corporate identity for its newest pharmaceutical marketing division in the U.S

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS042166

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel